<analysis>
**Action 1 (Site 2 sessions 9–10, then the interim).** The sessions are already booked, and backup dates exist. Two things still threaten them. The attendance condition depends on a single biosafety officer, whose inspections and illness have already cost January. Recruitment no-shows run at roughly 20%. Offering weekend sessions helps with timing but not with that officer's availability. Drafting the pooled interim by about 20 February is routine for Anthropic's team. CAISI accepting the interim for review is a separate matter, covered by Threat 5.
- **Failure:** Site 2 ends February at 9 or fewer sessions, or reaches 10 only after about 20 February, so submission slips into March.

**Action 2 (board memo).** Submitting the memo is certain. Counsel will trim the "honest assessment" wording somewhat, because the memo is discoverable, but the substance should survive. What the action is really trying to secure is the researcher extension through Q2 and a board that stays patient.
- **Failure:** the extension runs only to 31 March, and the board reads the "late February" v3 promise as a fourth slip in waiting.
- **Board decoupling GA from the harness:** handled by Threat 2, not counted here.
- **Hard limit:** CAISI's GA condition requires a valid harness method. So even if the board decouples, it can only direct management to prepare GA and press CAISI. It cannot ship GA itself.

**Action 3 (harness v3 design).** This is ambitious, and the prerequisites are shaky.
- The researcher extension is pending (tied to Action 2).
- Apollo's capacity is limited, and its authors are available only through March.
- CAISI pre-registration takes coordination.
- The claim that Opus 6 is "not eval-aware" is unsupported, since frontier models flag about 60% of evals as evals.
- Human-authored handoff plants already failed on authorship (AUC 0.94).
- The fingerprint and distribution problem is modelled by Threat 1.
- **Execution risk this action covers:** finishing the design by 15 February, pre-registering by 20 February, and staffing.
- **Cap regardless of roll:** no complete validation run, and no pass against the 0.55 gate, happens in February.

**Action 4 (Site 3 signature and sessions).** General counsel's signature is likely early in the month. After that, a new site has to stand up: its biosafety officer, participant recruitment, and staff training.
- **Base-case target:** 3–4 sessions by 28 February is aggressive.
- **Success:** 2 or more sessions.
- **Failure:** signature slips, or no sessions happen in February.

**Action 5 (validation-standard input).** Anthropic has standing channels with Commerce and CAISI, so delivering the input is easy. Getting the "quantitative preferred" framing adopted in staff text is harder. Coordinating with UK AISI is a low-probability sub-goal, because the UK works government-to-government. Watering-down of the standard is covered by Threat 3.

**Pre-declared branches for the harness.**
- **A3 succeeds, T1 does not materialise:** the design is complete and pre-registered with CAISI by about 20–25 February. Pre-validation reaches AUC below 0.60 on the non-handoff channels only. The main run is in March.
- **A3 succeeds, T1 materialises:** the methodology is pre-registered, but plants fail pre-validation (AUC ≥ 0.65). The run slips to March, and Apollo's window becomes binding.
- **A3 fails, T1 does not materialise:** the design slips, and pre-registration lands in early March.
- **A3 fails, T1 materialises:** the failures stack. Nothing is pre-registered, and a Opus 6 scratchpad eval-awareness note may appear (50% within this branch). The researcher lapse stacks only if Action 2 also fails.

**Pre-declared branches for the researcher extension.**
- **A2 succeeds:** extension through Q2.
- **A2 fails:** extension to 31 March only.
- **A2 fails and T2 materialises:** extension to 31 March, and the harness is recast internally as a post-GA commitment. The head of product safety owns the GA plan.
- **T2 materialises with A2 succeeding:** the board orders parallel GA preparation on the disclosure path, but the Q2 extension stands.

**Side threads (resolved by fixed mapping onto this month's rolls).**
- **Bank's Claude-Next request (P 35% that CAISI approves in February):** approved if the ones digit of the Action 1 roll is 0–3 (40%; I accept a 5-point difference).
- **Transition-text attribution surfacing publicly (P 15%):** surfaces if the Action 5 roll is 85 or higher.
- **Statute transmitted early, in February (P ~5%):** no; it goes in March.
- **OpenAI agentic GPT-7 ships in February (P 15%):** ships only if the Threat 4 roll is 85 or higher.
- **Jobs report:** released Friday 2 February.
- **Capability clock:** Claude-Next internal checkpoint reaches about 6.2–6.4 days. Public CI moves to 4.7, or 4.8 if Google ships.
</analysis>

<action_odds>
Action 1 [Site 2 completion + interim]: P(failure) 25%. Reason: the sessions are booked with backup dates, but a single biosafety officer and no-show rates (history: January lost 5 slots) are real risks. CAISI's review side is modelled separately.

Action 2 [Board GA memo + extension]: P(failure) 40%. Reason: submitting the memo is certain, but after three slips a frustrated board with the stock 25% down is unlikely to grant a full-Q2 extension on the strength of another optimistic date. Decoupling is left to Threat 2.

Action 3 [Harness v3 design]: P(failure) 50%. Reason: a tight 15/20 February schedule, dependence on the unresolved extension, Apollo's limited capacity, and pre-registration logistics. The fingerprint and distribution-shift risk is left to Threat 1. Capped: no gate pass in February.

Action 4 [Site 3 signature + sessions]: P(failure) 40%. Reason: the signature is likely, but standing up a new site mid-month and recruiting for 3–4 sessions in about 10 days is aggressive. Success means 2 or more sessions.

Action 5 [Validation-standard input]: P(failure) 35%. Reason: the channels exist and the input is well timed. UK alignment is unlikely either way. Success means the either/or framing, with quantitative coverage as the default, appears in staff working text.
</action_odds>

<threat_odds>
Threat 1 [Opus 6 fingerprint / handoff plants fail]: P(materialises) 50%. Adversary suggested 60%. Reason: two prior distribution-shift failures and robust model-attribution research make this more likely than not in expectation. Human surface edits and a partly human handoff set give some chance of passing on the non-handoff channels.

Threat 2 [Board decouples GA from harness]: P(materialises) 30%. Adversary suggested 45%. Reason: the pressure is real, but CAISI's GA condition requires a valid harness method, so decoupling would be a board directive to prepare and lobby, not a GA. That lowers the board's appetite for a formal decoupling vote this month.

Threat 3 [Disclosure off-ramp becomes floor]: P(materialises) 35%. Adversary suggested 40%. Reason: the player's own option (b) invites administrable loosening, and competitors will push for it. However, the transition text already contains "validated before release", and the draft is due only in March. Materialising here means the staff text trends that way, not final adoption.

Threat 4 [Securities complaint filed]: P(materialises) 20%. Adversary suggested 30%. Reason: many "investigations" never become filed suits, or take months. Filing within this specific month is less likely than the adversary implies, with no new corrective disclosure event in February.

Threat 5 [Google ships + interim stalls]: P(materialises) 25%, for the full threat (Google ships AND CAISI queries the pooling). Adversary suggested 45%/30%. Reason: pooling was informally pre-cleared in December, which lowers the chance of a pooling query, but adding Site 3 mid-study invites one. Declared nested mapping on the single roll:
- roll below 25: both happen;
- roll 25–49: Google ships at about 6.0 days (CI 4.8 public) with no interim delay;
- roll 50 or higher: no Google release in February.
This gives about a 50% chance of a February Google release, consistent with the leaks and DeepMind's repeated slips.
</threat_odds>
